EYP002 is a new first-in-class chemical series under lead optimization. Initially developed using inhibition of influenza replication as a phenotypic assay. Molecules modulate the activity of a small family of mitochondrial proteins, the NEET proteins encoded by three CISD genes. NEET proteins are unique in their ability to reversibly bind Fe-S clusters and transfer the cluster to acceptor apoproteins. In so doing, NEET proteins perform an important role in mitochondrial Fe/ROS homeostasis and are known to regulate mitochondrial metabolism, ageing and tumor cell survival. The scope for therapeutic application extends beyond infectious diseases with several other indications having been positively tested through in vitro and in vivo animal pharmacology studies (e.g. Metabolic Diseases, Oncology, and the rare genetic disease Wolfram Syndrome Type 2). ENYO Pharma believes the different target family selectivities within the chemical series will be developable in different therapeutic areas.
The company is open to discussions with potential partners to co-develop different sub-series in a risk-sharing relationship.